[{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Lupin Pharma Canada","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aytu BioPharma \/ Lupin Pharma Canada","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Lupin Pharma Canada"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Divestment","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Aytu BioPharma \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Enzastaurin","moa":"PKC-beta","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aytu BioPharma \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Aytu BioPharma \/ Canaccord Genuity"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enzastaurin","moa":"PKC-beta","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aytu BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aytu BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating, Extended Release","sponsorNew":"Aytu BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Aytu BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Aytu BioPharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The agreement aims for the distribution and supply for Aytu's Adzenys XR-ODT and Cotempla XR-ODT product lines for the treatment of ADHD in Canada.

                          Product Name : Adzenys XR-ODT

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 10, 2024

                          Lead Product(s) : Amphetamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Lupin Pharma Canada

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.

                          Product Name : Cotempla

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          October 26, 2023

                          Lead Product(s) : Methylphenidate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : AR101 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K and AKT pathways.

                          Product Name : AR101

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 16, 2022

                          Lead Product(s) : Enzastaurin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The Company intends to use the net proceeds from the Offering for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome (VEDS).

                          Product Name : AR101

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 15, 2022

                          Lead Product(s) : Enzastaurin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Canaccord Genuity

                          Deal Size : $10.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : XR-ODT is FDA-Approved as Bioequivalent to Adderall XR is the only FDA-approved, extended-release, orally-disintegrating tablet formulation of amphetamine,indicated for the treatment of ADHD in patients six years and older.

                          Product Name : Adzenys XR-ODT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 10, 2022

                          Lead Product(s) : Amphetamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Acerus will acquire all remaining rights to Natesto in the United States from Aytu. Acerus will assume all product responsibilities associated with Natesto.

                          Product Name : Natesto

                          Product Type : Hormone

                          Upfront Cash : $7.5 million

                          January 04, 2021

                          Lead Product(s) : Testosterone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Acerus Pharmaceuticals

                          Deal Size : $7.5 million

                          Deal Type : Divestment

                          blank